<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39424894</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Similar humoral responses but distinct CD4<sup>+</sup> T cell transcriptomic profiles in older adults elicited by MF59 adjuvanted and high dose influenza vaccines.</ArticleTitle><Pagination><StartPage>24420</StartPage><MedlinePgn>24420</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24420</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75250-2</ELocationID><Abstract><AbstractText>Older age (≥ 65 years) is associated with impaired responses to influenza vaccination, leading to the preferential recommendation of MF59-adjuvanted (MF59Flu) or high-dose (HDFlu) influenza vaccines for this age group in the United States. Herein, we characterized transcriptomic profiles of CD4<sup>+</sup> T cells isolated from 234 recipients (≥ 65 years) of either MF59Flu or HDFlu vaccine, prior to vaccination and 28 days thereafter. We identified 412 and 645 differentially expressed genes (DEGs) in CD4<sup>+</sup> T cells of older adults after receiving MF59Flu and HDFlu, respectively. DEGs in CD4<sup>+</sup> T cells of MF59Flu recipients were enriched in 14 KEGG pathways, all of which were downregulated. DEGs in CD4<sup>+</sup> T cells of HDFlu recipients were enriched in 11 upregulated pathways and 20 downregulated pathways. CD4<sup>+</sup> T cells in both vaccine groups shared 50 upregulated genes and 75 downregulated genes, all of which were enriched in 7 KEGG pathways. The remaining 287 and 520 DEGs were specifically associated with MF59Flu and HDFlu, respectively. Unexpectedly, none of these DEGs was significantly correlated with influenza A/H3N2-specific HAI titers, suggesting these DEGs at the individual level may have a limited role in protection against influenza. Our findings emphasize the need for further investigation into other factors influencing immunity against influenza in older adults.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quach</LastName><ForeName>Huy Quang</ForeName><Initials>HQ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Vaccine Research Group, Mayo Clinic, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haralambieva</LastName><ForeName>Iana H</ForeName><Initials>IH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Vaccine Research Group, Mayo Clinic, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goergen</LastName><ForeName>Krista M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grill</LastName><ForeName>Diane E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ovsyannikova</LastName><ForeName>Inna G</ForeName><Initials>IG</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Vaccine Research Group, Mayo Clinic, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poland</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Vaccine Research Group, Mayo Clinic, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Vaccine Research Group, Mayo Clinic, Rochester, MN, 55905, USA. kennedy.rick@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AI132348</GrantID><Agency>National Institute of Allergy and Infectious Diseases</Agency><Country /></Grant><Grant><GrantID>75N93019C00052</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C089950">MF59 oil emulsion</NameOfSubstance></Chemical><Chemical><RegistryNumber>7QWM220FJH</RegistryNumber><NameOfSubstance UI="D013185">Squalene</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011136">Polysorbates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013185" MajorTopicYN="Y">Squalene</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="Y">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011136" MajorTopicYN="Y">Polysorbates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="Y">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD4+ T cells</Keyword><Keyword MajorTopicYN="N">Gene expression profiling</Keyword><Keyword MajorTopicYN="N">High-dose influenza vaccine</Keyword><Keyword MajorTopicYN="N">MF59-adjuvanted influenza vaccine</Keyword><Keyword MajorTopicYN="N">Older adults</Keyword></KeywordList><CoiStatement>Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland provides consultative advice to AiZtech; GlaxoSmithKline; Invivyd; Janssen Global Services, LLC; Merck &amp; Co. Inc.; Moderna; Novavax; and Syneos Health. Drs. Poland and Ovsyannikova hold patents related to vaccinia and measles peptide vaccines. Drs. Kennedy, Poland, and Ovsyannikova hold a patent related to vaccinia peptide vaccines. Drs. Kennedy, Poland, and Ovsyannikova have received grant funding and royalties from ICW Ventures for pre-clinical studies on a peptide-based COVID-19 vaccine. Drs. Kennedy, Poland, Ovsyannikova and Haralambieva hold a patent related to the impact of single nucleotide polymorphisms on measles vaccine immunity. Dr. Kennedy has received funding from Merck Research Laboratories to study waning immunity to mumps vaccine. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>23</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39424894</ArticleId><ArticleId IdType="pmc">PMC11489691</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75250-2</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75250-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goodwin, K., Viboud, C. &amp; Simonsen, L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 24, 1159–1169. 10.1016/j.vaccine.2005.08.105 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16213065</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen, J. C., Toapanta, F. R., Chen, W. &amp; Tennant, S. M. Understanding immunosenescence and its impact on vaccination of older adults. Vaccine. 38, 8264–8272. 10.1016/j.vaccine.2020.11.002 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7719605</ArticleId><ArticleId IdType="pubmed">33229108</ArticleId></ArticleIdList></Reference><Reference><Citation>Goronzy, J. J. &amp; Weyand, C. M. Understanding immunosenescence to improve responses to vaccines. Nat. Immunol.14, 428–436 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4183346</ArticleId><ArticleId IdType="pubmed">23598398</ArticleId></ArticleIdList></Reference><Reference><Citation>Haq, K. &amp; McElhaney, J. E. Immunosenescence: influenza vaccination and the elderly. Curr. Opin. Immunol.29, 38–42 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24769424</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer, F. et al. Influenza. Nat. Rev. Dis. Primers. 4, 3. 10.1038/s41572-018-0002-y (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097467</ArticleId><ArticleId IdType="pubmed">29955068</ArticleId></ArticleIdList></Reference><Reference><Citation>United Nations Department of Economic and Social Affairs, Population Division. World Population Prospects 2022: Summary of Results. UN DESA/POP/2022/TR/NO. 3. https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/wpp2022_summary_of_results.pdf  (2022).</Citation></Reference><Reference><Citation>Cowling, B. J. et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a Randomized, Controlled Trial. Clin. Infect. Dis.71, 1704–1714. 10.1093/cid/ciz1034 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289658</ArticleId><ArticleId IdType="pubmed">31828291</ArticleId></ArticleIdList></Reference><Reference><Citation>DiazGranados, C. A. et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N. Engl. J. Med.371, 635–645 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25119609</ArticleId></ArticleIdList></Reference><Reference><Citation>Domnich, A. et al. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine. 35, 513–520. 10.1016/j.vaccine.2016.12.011 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28024956</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey, S. E. et al. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 32, 5027–5034. 10.1016/j.vaccine.2014.07.013 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25045825</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravenstein, S. et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respiratory Med.5, 738–746 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28736045</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapi, F. et al. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly. Expert Rev. Vaccines. 18, 663–670 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31155968</ArticleId></ArticleIdList></Reference><Reference><Citation>McConeghy, K. W. et al. Cluster-randomized Trial of Adjuvanted Versus Nonadjuvanted Trivalent Influenza Vaccine in 823 US nursing homes. Clin. Infect. Dis.73, e4237–e4243 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32882710</ArticleId></ArticleIdList></Reference><Reference><Citation>Domnich, A. &amp; de Waure, C. Comparative effectiveness of adjuvanted versus high-dose seasonal influenza vaccines for older adults: a systematic review and meta-analysis. Int. J. Infect. Dis.122, 855–863. 10.1016/j.ijid.2022.07.048 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35878803</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmader, K. E. et al. Immunogenicity of adjuvanted versus high-dose inactivated influenza vaccines in older adults: a randomized clinical trial. Immun. Ageing. 20, 30. 10.1186/s12979-023-00355-7 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10314373</ArticleId><ArticleId IdType="pubmed">37393237</ArticleId></ArticleIdList></Reference><Reference><Citation>McElhaney, J. E. et al. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol.176, 6333–6339. 10.4049/jimmunol.176.10.6333 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16670345</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosendahl Huber, S. K. et al. Immunogenicity of influenza vaccines: evidence for differential effect of secondary vaccination on humoral and cellular immunity. Front. Immunol.9, 3103 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6362424</ArticleId><ArticleId IdType="pubmed">30761157</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, W. H. et al. Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. Vaccine. 29, 2865–2873 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3070775</ArticleId><ArticleId IdType="pubmed">21352939</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen, J. M., Gerlach, T., Elbahesh, H., Rimmelzwaan, G. F. &amp; Saletti, G. Influenza virus-specific CD4 + and CD8 + T cell-mediated immunity induced by infection and vaccination. J. Clin. Virol.119, 44–52. 10.1016/j.jcv.2019.08.009 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31491709</ArticleId></ArticleIdList></Reference><Reference><Citation>Sant, A. J., DiPiazza, A. T., Nayak, J. L., Rattan, A. &amp; Richards, K. A. CD4 T cells in protection from influenza virus: viral antigen specificity and functional potential. Immunol. Rev.284, 91–105. 10.1111/imr.12662 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6070306</ArticleId><ArticleId IdType="pubmed">29944766</ArticleId></ArticleIdList></Reference><Reference><Citation>Zens, K. D. &amp; Farber, D. L. Memory CD4 T cells in influenza. Curr. Top. Microbiol. Immunol.386, 399–421. 10.1007/82_2014_401 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339101</ArticleId><ArticleId IdType="pubmed">25005927</ArticleId></ArticleIdList></Reference><Reference><Citation>Haralambieva, I. H. et al. T Cell Transcriptional Signatures of Influenza A/H3N2 antibody response to high dose influenza and Adjuvanted Influenza Vaccine in older adults. Viruses. 14, 2763 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9786771</ArticleId><ArticleId IdType="pubmed">36560767</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, H. et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008. Clin. Infect. Dis.54, 1427–1436. 10.1093/cid/cis211 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334364</ArticleId><ArticleId IdType="pubmed">22495079</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichert, T. A. et al. Influenza and the winter increase in mortality in the United States, 1959–1999. Am. J. Epidemiol.160, 492–502. 10.1093/aje/kwh227 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15321847</ArticleId></ArticleIdList></Reference><Reference><Citation>Belongia, E. A. et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet. Infect. Dis. 16, 942–951 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27061888</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer, W., Palache, A., Lüchters, G., Nauta, J. &amp; Osterhaus, A. Seroprotection rate, mean Fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?. Virus Res.103, 125–132 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15163500</ArticleId></ArticleIdList></Reference><Reference><Citation>Luckheeram, R. V., Zhou, R., Verma, A. D. &amp; Xia, B. CD4⁺T cells: differentiation and functions. Clin. Dev. Immunol. 2012, 925135. 10.1155/2012/925135 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312336</ArticleId><ArticleId IdType="pubmed">22474485</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain, S. L., McKinstry, K. K. &amp; Strutt, T. M. Expanding roles for CD4 + T cells in immunity to viruses. Nat. Rev. Immunol.12, 136–148. 10.1038/nri3152 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3764486</ArticleId><ArticleId IdType="pubmed">22266691</ArticleId></ArticleIdList></Reference><Reference><Citation>Prigge, A. D., Ma, R., Coates, B. M., Singer, B. D. &amp; Ridge, K. M. Age-dependent differences in T-Cell responses to Influenza A Virus. Am. J. Respir Cell. Mol. Biol.63, 415–423. 10.1165/rcmb.2020-0169TR (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7528914</ArticleId><ArticleId IdType="pubmed">32609537</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaur, P., Munjhal, A. &amp; Lal, S. K. Influenza virus and cell signaling pathways. Med. Sci. Monit.17, Ra148-154. 10.12659/msm.881801 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3539548</ArticleId><ArticleId IdType="pubmed">21629204</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapira, S. D. et al. A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell. 139, 1255–1267. 10.1016/j.cell.2009.12.018 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892837</ArticleId><ArticleId IdType="pubmed">20064372</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko, E. J. &amp; Kang, S. M. Immunology and efficacy of MF59-adjuvanted vaccines. Hum. Vaccin Immunother. 14, 3041–3045. 10.1080/21645515.2018.1495301 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6343625</ArticleId><ArticleId IdType="pubmed">30015572</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Hagan, D. T., Ott, G. S., De Gregorio, E. &amp; Seubert, A. The mechanism of action of MF59 – an innately attractive adjuvant formulation. Vaccine. 30, 4341–4348. 10.1016/j.vaccine.2011.09.061 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22682289</ArticleId></ArticleIdList></Reference><Reference><Citation>DiazGranados, C. A. et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N. Engl. J. Med.371, 635–645. 10.1056/NEJMoa1315727 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25119609</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, G. et al. Identification of critical genes and pathways for Influenza A Virus infections via Bioinformatics Analysis. Viruses. 14. 10.3390/v14081625 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9332270</ArticleId><ArticleId IdType="pubmed">35893690</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, W. &amp; Liu, H. T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res.12, 9–18. 10.1038/sj.cr.7290105 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11942415</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu, S., Binder, R. J., Suto, R., Anderson, K. M. &amp; Srivastava, P. K. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway. Int. Immunol.12, 1539–1546. 10.1093/intimm/12.11.1539 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11058573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, S., Zhao, Y., Wang, D. &amp; Chen, Z. Mode of Action of Heat shock protein (HSP) inhibitors against viruses through host HSP and Virus interactions. Genes. 14, 792 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10138296</ArticleId><ArticleId IdType="pubmed">37107550</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, X. &amp; Yu, W. Heat shock proteins and viral infection. Front. Immunol.13, 947789. 10.3389/fimmu.2022.947789 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9389079</ArticleId><ArticleId IdType="pubmed">35990630</ArticleId></ArticleIdList></Reference><Reference><Citation>Haralambieva, I. H. et al. The impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects. PloS One. 10, e0122282 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4376784</ArticleId><ArticleId IdType="pubmed">25816015</ArticleId></ArticleIdList></Reference><Reference><Citation>Quach, H. Q. et al. The influence of sex, BMI, and age on cellular and humoral immune responses against measles after a 3rd dose of MMR vaccine. J. Infect. Dis.10.1093/infdis/jiac351 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10205623</ArticleId><ArticleId IdType="pubmed">35994504</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigt, E. A. et al. Sex differences in older adults’ immune responses to seasonal influenza vaccination. Front. Immunol.10, 180 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6400991</ArticleId><ArticleId IdType="pubmed">30873150</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg, E. L., Shaw, A. C. &amp; Montgomery, R. R. How inflammation blunts innate immunity in aging. Interdiscip Top. Gerontol. Geriatr.43, 1–17. 10.1159/000504480 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8063508</ArticleId><ArticleId IdType="pubmed">32294641</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild, K. et al. Pre-existing immunity and vaccine history determine hemagglutinin-specific CD4 T cell and IgG response following seasonal influenza vaccination. Nat. Commun.12, 6720. 10.1038/s41467-021-27064-3 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8602312</ArticleId><ArticleId IdType="pubmed">34795301</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, F. X. et al. Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice. iScience. 25, 105479. 10.1016/j.isci.2022.105479 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9625849</ArticleId><ArticleId IdType="pubmed">36338436</ArticleId></ArticleIdList></Reference><Reference><Citation>Uversky, V. N., Redwan, E. M., Makis, W. &amp; Rubio-Casillas, A. IgG4 antibodies Induced by repeated vaccination may generate Immune Tolerance to the SARS-CoV-2 Spike Protein. Vaccines (Basel). 11. 10.3390/vaccines11050991 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10222767</ArticleId><ArticleId IdType="pubmed">37243095</ArticleId></ArticleIdList></Reference><Reference><Citation>Tani, Y. et al. Five doses of the mRNA vaccination potentially suppress ancestral-strain stimulated SARS-CoV2-specific cellular immunity: a cohort study from the Fukushima vaccination community survey, Japan. Front. Immunol.14, 1240425. 10.3389/fimmu.2023.1240425 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10469480</ArticleId><ArticleId IdType="pubmed">37662950</ArticleId></ArticleIdList></Reference><Reference><Citation>McGargill, M. A. et al. Immune tolerance limits effective immunity to epitopes targeted by universal influenza vaccines. J. Immunol. 204 245.244-245.244. 10.4049/jimmunol.204.Supp.245.4 (2020).</Citation></Reference><Reference><Citation>Jacobson, R. M. et al. Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers. Hum. Vaccin Immunother. 11, 961–969. 10.1080/21645515.2015.1011990 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4514374</ArticleId><ArticleId IdType="pubmed">25835513</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohmit, S. E., Petrie, J. G., Cross, R. T., Johnson, E. &amp; Monto, A. S. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J. Infect. Dis.204, 1879–1885. 10.1093/infdis/jir661 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21998477</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrie, J. G., Ohmit, S. E., Johnson, E., Cross, R. T. &amp; Monto, A. S. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J. Infect. Dis.203, 1309–1315. 10.1093/infdis/jir015 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069734</ArticleId><ArticleId IdType="pubmed">21378375</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann, M. T. et al. Integration of Immune Cell populations, mRNA-Seq, and CpG methylation to Better Predict Humoral Immunity to Influenza Vaccination: dependence of mRNA-Seq/CpG methylation on Immune Cell populations. Front. Immunol.8, 445. 10.3389/fimmu.2017.00445 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5399034</ArticleId><ArticleId IdType="pubmed">28484452</ArticleId></ArticleIdList></Reference><Reference><Citation>Haralambieva, I. H. et al. Transcriptional signatures associated with rubella virus-specific humoral immunity after a third dose of MMR vaccine in women of childbearing age. Eur. J. Immunol.51, 1824–1838. 10.1002/eji.202049054 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9841595</ArticleId><ArticleId IdType="pubmed">33818775</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovsyannikova, I. G. et al. Gene signatures associated with adaptive humoral immunity following seasonal influenza A/H1N1 vaccination. Genes Immun.17, 371–379 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5133148</ArticleId><ArticleId IdType="pubmed">27534615</ArticleId></ArticleIdList></Reference><Reference><Citation>Haralambieva, I. H. et al. Transcriptional signatures of influenza A/H1N1-specific IgG memory-like B cell response in older individuals. Vaccine. 34, 3993–4002 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5520794</ArticleId><ArticleId IdType="pubmed">27317456</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalari, K. R. et al. MAP-RSeq: Mayo analysis pipeline for RNA sequencing. BMC Bioinform.15, 1–11 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4228501</ArticleId><ArticleId IdType="pubmed">24972667</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen, K. D., Irizarry, R. A. &amp; Wu, Z. Removing technical variability in RNA-seq data using conditional quantile normalization. Biostatistics. 13, 204–216 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297825</ArticleId><ArticleId IdType="pubmed">22285995</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen, K. D., Irizarry, R. A. &amp; Wu, Z. Removing technical variability in RNA-seq data using conditional quantile normalization. Biostatistics. 13, 204–216. 10.1093/biostatistics/kxr054 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297825</ArticleId><ArticleId IdType="pubmed">22285995</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeger, S. L. &amp; Liang, K. Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 42, 121–130 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">3719049</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, G., Wang, L. G., Han, Y. &amp; He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 16, 284–287. 10.1089/omi.2011.0118 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci.28, 1947–1951. 10.1002/pro.3715 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6798127</ArticleId><ArticleId IdType="pubmed">31441146</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. &amp; Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res.51, D587-d592. 10.1093/nar/gkac963 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9825424</ArticleId><ArticleId IdType="pubmed">36300620</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa, M. &amp; Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res.28, 27–30. 10.1093/nar/28.1.27 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102409</ArticleId><ArticleId IdType="pubmed">10592173</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey, J. D. A direct approach to false discovery rates. J. Royal Stat. Soc. Ser. B: Stat. Methodol.64, 479–498 (2002).</Citation></Reference><Reference><Citation>Benjamini, Y. &amp; Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Stat. Soc.: Ser. B (Methodol.). 57, 289–300 (1995).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>